Moving the Needle Forward with Locoregional Treatment in Unresectable Cholangiocarcinoma - The Jury Is Still Out

TY - JOUR

T1 - Moving the Needle Forward with Locoregional Treatment in Unresectable Cholangiocarcinoma - The Jury Is Still Out

AU - Scott, Aaron J.

AU - Shroff, Rachna T.

N1 - Funding Information: Conflict of Interest Disclosures: Dr Scott reported receiving personal fees from Exelixis, FivePrime, Genentech, and Incyte outside the submitted work; is a paid advisory board member for Exelixis Pharmaceuticals; and has received research funding from FivePrime Therapeutics, Exelixis Pharmaceuticals, Genentech, and Incyte Corporation. Dr Shroff reported receiving grants and personal fees from Merck, Exelixis, and QED Therapeutics; personal fees from Agios, Seattle Genetics, and Debio Pharm; grants from Pieris, Taiho, and Halozyme outside the submitted work; is a paid advisory board member for Merck, Seattle Genetics, Exelixis Pharmaceuticals, QED Therapeutics, and Debiopharm; and is a paid consultant for Agios. 31 10 2019 09 01 2020 January 2020 6 1 29 31 16 08 2019 19 08 2019 Copyright 2019 American Medical Association. All Rights Reserved. ced190018.pdf

PY - 2020/1

Y1 - 2020/1

UR - http://www.scopus.com/inward/record.url?scp=85074487849&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85074487849&partnerID=8YFLogxK

U2 - 10.1001/jamaoncol.2019.3691

DO - 10.1001/jamaoncol.2019.3691

M3 - Editorial

C2 - 31670748

SN - 2374-2437

VL - 6

SP - 29

EP - 31

JO - JAMA Oncology

JF - JAMA Oncology

IS - 1

ER -